Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00949247 · ClinicalTrials.gov registry record · Early Phase 1

Docetaxel,Carboplatin,Trastuzumab and Bevacizumab for Breast Cancer and Bone Marrow Micrometastases

A Early Phase 1 study of Breast Cancer, sponsored by Case Comprehensive Cancer Center.

Completed
Registry status
Early Phase 1
Development phase
20
Enrollment target
5
Study locations

NCT00949247 is a Early Phase 1 study of Breast Cancer that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 20 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 5 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00949247, a Early Phase 1 study of Breast Cancer, has completed, sponsored by Case Comprehensive Cancer Center.

COMPLETED
Registry status
Early Phase 1
Development phase
20 participants
Enrollment target
5
Study locations

Study Summary

RATIONALE: Drugs used in chemotherapy, such as docetaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as trastuzumab and bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving chemotherapy together with monoclonal antibody therapy may kill more tumor cells. PURPOSE: This clinical trial is studying how well giving docetaxel and carboplatin together with trastuzumab and bevacizumab works in treating patients with stage I, stage II, or stage III breast cancer and bone marrow micrometastases.

Conditions Studied

Breast Cancer

Interventions

  • OTHER laboratory biomarker analysis
  • DRUG carboplatin
  • DRUG docetaxel
  • BIOLOGICAL trastuzumab
  • BIOLOGICAL bevacizumab

Study Locations (5)

Ohio

  • Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center - Cleveland
  • Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center - Cleveland
  • University Hospitals Monarch - Mayfield Heights
  • University Hospitals Chagrin Highlands Medical Center - Orange
  • University Hospitals Westlake - Westlake

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2009-12
Est. Completion 2013-01
Phase Early Phase 1

Sponsor

Case Comprehensive Cancer Center

407 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00949247

The ClinicalTrials.gov registry entry for NCT00949247 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which laboratory biomarker analysis is the first listed.

NCT00949247 reports 5 study locations spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT00949247 about?

NCT00949247 is a clinical study titled "Docetaxel,Carboplatin,Trastuzumab and Bevacizumab for Breast Cancer and Bone Marrow Micrometastases". RATIONALE: Drugs used in chemotherapy, such as docetaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as trastuzumab and bevacizumab, can block tumor growth in different ways. Som...

What is the current status of trial NCT00949247?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2009-12. Estimated completion is 2013-01.

What conditions does trial NCT00949247 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT00949247?

The interventions under investigation include: laboratory biomarker analysis (OTHER), carboplatin (DRUG), docetaxel (DRUG), trastuzumab (BIOLOGICAL), bevacizumab (BIOLOGICAL).

Who is sponsoring clinical trial NCT00949247?

This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00949247 being conducted?

This trial has 5 study locations across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

Ohio

All trials with a study site in Ohio

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.